FDA approves first RSV vaccine, a long-sought scientific achievement
The FDA has approved the first-ever vaccine for respiratory syncytial virus, or RSV, completing an elusive quest that has been decades in the making.
The Food and Drug Administration on Wednesday licensed the first-ever vaccine for respiratory syncytial virus, or RSV, completing an elusive quest that has been decades in the making. The product, GSK’s Arexvy, was approved for adults ages 60 and older.
GSK beat a crowded field of competitors to cross the finish line first. A vaccine that was developed by Pfizer and aimed at the same demographic is expected to be approved by the end of the month.
What's Your Reaction?
